KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone857-999-0075
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.13 million
Profitability
Miscellaneous
Employees33
Next Earnings Date12/13/2019 (Estimated)
OptionableNot Optionable
Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions
What is Kalvista Pharmaceuticals' stock symbol?
Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."
How were Kalvista Pharmaceuticals' earnings last quarter?
Kalvista Pharmaceuticals Inc (NASDAQ:KALV) posted its quarterly earnings data on Monday, September, 9th. The specialty pharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.62) by $0.20. The specialty pharmaceutical company had revenue of $3.37 million for the quarter, compared to analyst estimates of $3.24 million. Kalvista Pharmaceuticals had a negative net margin of 144.64% and a negative return on equity of 22.29%. View Kalvista Pharmaceuticals' Earnings History.
When is Kalvista Pharmaceuticals' next earnings date?
What price target have analysts set for KALV?
7 analysts have issued 1-year price objectives for Kalvista Pharmaceuticals' stock. Their predictions range from $30.00 to $35.00. On average, they anticipate Kalvista Pharmaceuticals' stock price to reach $31.50 in the next twelve months. This suggests a possible upside of 191.4% from the stock's current price. View Analyst Price Targets for Kalvista Pharmaceuticals.
What is the consensus analysts' recommendation for Kalvista Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Kalvista Pharmaceuticals.
Has Kalvista Pharmaceuticals been receiving favorable news coverage?
Media headlines about KALV stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Kalvista Pharmaceuticals earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Kalvista Pharmaceuticals.
Who are some of Kalvista Pharmaceuticals' key competitors?
Some companies that are related to Kalvista Pharmaceuticals include Endo International (ENDP), CannTrust (CNTTF), Omeros (OMER), Cara Therapeutics (CARA), Emisphere Technologies (EMIS), ZEALAND PHARMA/S (ZEAL), Rhythm Pharmaceuticals (RYTM), Organogenesis (ORGO), Principia Biopharma (PRNB), Wave Life Sciences (WVE), ZIOPHARM Oncology (ZIOP), Stoke Therapeutics (STOK), Vanda Pharmaceuticals (VNDA), Vectura Group (VEGPF) and Cytokinetics (CYTK).
What other stocks do shareholders of Kalvista Pharmaceuticals own?
Who are Kalvista Pharmaceuticals' key executives?
Kalvista Pharmaceuticals' management team includes the folowing people:
- Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
- Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
- Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
- Mr. John B. McKune, VP of Fin. (Age 43)
- Dr. Edward P. Feener, Chief Scientific Officer (Age 59)
How do I buy shares of Kalvista Pharmaceuticals?
Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Kalvista Pharmaceuticals' stock price today?
One share of KALV stock can currently be purchased for approximately $10.81.
How big of a company is Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals has a market capitalization of $192.63 million and generates $16.13 million in revenue each year. The specialty pharmaceutical company earns $-20,820,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.View Additional Information About Kalvista Pharmaceuticals.
What is Kalvista Pharmaceuticals' official website?
How can I contact Kalvista Pharmaceuticals?
Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]
MarketBeat Community Rating for Kalvista Pharmaceuticals (NASDAQ KALV)
MarketBeat's community ratings are surveys of what our community members think about Kalvista Pharmaceuticals and other stocks. Vote "Outperform" if you believe KALV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KALV will underperform the S&P 500 over the long term. You may vote once every thirty days.
